Church & Dwight
CHD
$98.80
+1.43%
Church & Dwight Co., Inc. is a leading consumer packaged goods company that produces and markets a diverse portfolio of household and personal care products, including laundry detergents, cat litter, oral care, deodorants, and nasal care items, primarily under the iconic Arm & Hammer brand. The company holds a strong market position as a niche player with a focus on value-oriented, essential products, and its portfolio also includes brands like OxiClean, Batiste, Vitafusion, and TheraBreath, which together with Arm & Hammer account for about 70% of sales. The current investor narrative centers on the company's ability to maintain steady growth amid a challenging consumer environment, with recent acquisitions like Touchland expanding its product reach, while investors debate the sustainability of its growth and margin performance in the face of input cost pressures and competitive dynamics.…
CHD
Church & Dwight
$98.80
Investment Opinion: Should I buy CHD Today?
Based on the analysis, CHD is rated a 'Hold' with a thesis that its defensive qualities and margin stability justify a premium, but the lack of growth limits upside. The consensus 'Buy' rating and average target of $105.37 suggest modest upside, but the stock's premium valuation (PE 27.6x vs. industry 22x) leaves little room for error. Investors should wait for a better entry point or evidence of growth acceleration.
Sign up to view all
CHD 12-Month Price Forecast
The AI assessment is neutral, reflecting balanced risks and rewards. CHD's defensive nature and margin stability are positives, but the lack of growth and premium valuation cap upside. The stance would upgrade to bullish if revenue growth exceeds 3% and PE compresses below 25x, or downgrade to bearish if margins decline and volume growth turns negative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Church & Dwight's 12-month outlook, with a consensus price target around $105.37 and implied upside of +6.7% versus the current price.
Average Target
$105.37
0 analysts
Implied Upside
+6.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$78 - $115
Analyst target range
The stock is covered by 19 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 2.24 (where 1 is Strong Buy and 5 is Sell). The average target price is $105.37, which implies a 4.0% upside from the current price of $101.30. The distribution includes 10 Buy ratings, 7 Hold, and 2 Sell, indicating a generally positive but not overly enthusiastic outlook. The target price range is wide, from $78.00 to $115.00, reflecting significant uncertainty about the company's future performance. The high target assumes continued market share gains and margin expansion, while the low target prices in potential volume declines and competitive pressures. Recent ratings actions have been mostly neutral, with no major upgrades or downgrades, suggesting that analysts are waiting for clearer signs of growth acceleration.
Bulls vs Bears: CHD Investment Factors
CHD presents a mixed picture: strong brand portfolio, solid profitability, and defensive characteristics are offset by stagnant revenue growth and a premium valuation. The bull case relies on margin expansion and market share gains, while the bear case hinges on continued top-line stagnation and multiple compression. Currently, the evidence slightly favors the bull side due to improving gross margins and analyst optimism, but the lack of revenue growth is the key tension. If CHD can reignite volume growth, the stock could re-rate higher; otherwise, the premium valuation may prove unsustainable.
Bullish
- Strong brand portfolio with pricing power: CHD's iconic brands like Arm & Hammer, OxiClean, and Batiste account for ~70% of sales, enabling consistent market share and pricing power. This is evidenced by gross margin expansion to 46.4% in Q1 2026 from 45.0% in Q3 2025, despite flat revenue.
- Healthy profitability and cash flow: Net margin improved to 14.7% in Q1 2026, and free cash flow TTM stands at $1.07 billion, supporting dividend payments (yield 1.4%) and strategic acquisitions like Touchland. ROE is strong at 18.4%, indicating efficient capital use.
- Low beta and defensive nature: With a beta of 0.47, CHD offers stability in volatile markets, making it a defensive holding. Its essential consumer products maintain demand even during economic downturns, as seen in its 1-year gain of 9.4% despite market turbulence.
- Analyst consensus and upside potential: 19 analysts rate CHD a 'Buy' with an average target of $105.37, implying 4.0% upside. The high target of $115 suggests potential for 13.5% gains if growth accelerates, reflecting confidence in the company's strategic direction.
Bearish
- Stagnant revenue growth: Q1 2026 revenue of $1.469 billion grew only 0.15% YoY, and Q4 2025 revenue of $1.644 billion was flat. This lack of top-line growth suggests market saturation and intense competition, limiting earnings expansion.
- Premium valuation with limited margin of safety: Trailing PE of 27.6x and forward PE of 25.1x are above the industry average of 22x, implying a 25% premium. With minimal growth, any earnings miss could trigger multiple compression, as seen in the stock's 17.65% max drawdown.
- Relative underperformance vs. market: CHD's 1-year return of 9.4% lags the S&P 500's 20.4% gain, and its 6-month return is -0.15% vs. S&P's 13.87%. This underperformance may persist if growth remains muted, making it less attractive for growth-oriented investors.
- High payout ratio and limited dividend growth: The payout ratio is 39%, and the dividend yield is only 1.4%, which is modest for a defensive stock. With flat earnings, dividend increases may be limited, reducing income appeal.
CHD Technical Analysis
The stock is in a recovery phase, having rebounded from its 52-week low of $81.33 to a current price of $101.30, which is approximately 95.5% of its 52-week range (with a high of $106.04). Over the past year, the stock has gained 9.4%, but this lags the S&P 500's 20.4% gain, indicating relative underperformance. The price is currently near the upper end of its range, suggesting momentum is building, but the stock is not yet at overbought levels, as it remains about 4.5% below the high.
Beta
0.47
0.47x market volatility
Max Drawdown
-16.8%
Largest decline past year
52-Week Range
$81-$106
Price range past year
Annual Return
+4.0%
Cumulative gain past year
| Period | CHD Return | S&P 500 |
|---|---|---|
| 1m | +1.7% | +2.5% |
| 3m | +2.6% | +2.7% |
| 6m | -4.2% | +11.1% |
| 1y | +4.0% | +20.5% |
| ytd | +19.6% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CHD Fundamental Analysis
Revenue growth has been nearly flat, with the most recent quarter (Q1 2026) showing revenue of $1.469 billion, a mere 0.15% increase year-over-year. This follows a pattern of modest growth, with Q4 2025 revenue of $1.644 billion and Q3 2025 revenue of $1.586 billion, indicating a deceleration from earlier periods. The company's net income for Q1 2026 was $216.3 million, with a net margin of 14.7%, which is healthy, but the lack of top-line growth raises concerns about the company's ability to drive volume in a competitive market. The gross margin improved to 46.4% in Q1 2026, up from 45.0% in Q3 2025, suggesting some cost relief, but operating margin remained stable at around 19.8%.
Quarterly Revenue
$1.5B
2026-03
Revenue YoY Growth
+0.1%
YoY Comparison
Gross Margin
46.4%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CHD Overvalued?
Given that net income is positive, the primary valuation metric is the price-to-earnings (PE) ratio. The trailing PE is 27.6x, while the forward PE is 25.1x, implying that the market expects modest earnings growth of about 10% over the next year. This gap is relatively small, suggesting that the market's growth expectations are conservative. Compared to the industry average PE of 22x (based on available data), CHD trades at a 25% premium, which may be justified by its strong brand portfolio and consistent profitability, but it also leaves little room for error.
PE
27.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 22x~39x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a debt-to-equity ratio of 0.55, which is manageable but not negligible, and interest expenses of $24 million in Q1 2026. The company's flat revenue growth (0.15% YoY) increases sensitivity to cost pressures, though gross margin expansion to 46.4% provides some buffer. Free cash flow of $1.07 billion is healthy, but the payout ratio of 39% limits reinvestment capacity. Earnings volatility is evident from Q3 2024's net loss of $75 million, though this was an anomaly due to one-time charges.
FAQ
The key risks include: 1) Financial: high payout ratio (39%) and debt-to-equity of 0.55, which could limit flexibility. 2) Competitive: intense competition from private labels and larger players like P&G, which could pressure market share. 3) Macro: sensitivity to input costs and consumer spending, though beta of 0.47 reduces market risk. 4) Company-specific: reliance on US market (80% of sales) and concentration in a few brands. The most severe risk is a prolonged volume decline, which could lead to a de-rating toward the 52-week low of $81.33.
The 12-month forecast is a base case with 55% probability, targeting $100-$106, aligning with the analyst average of $105.37. The bull case (25% probability) targets $105-$115, driven by growth acceleration, while the bear case (20% probability) targets $78-$95, reflecting competitive pressures. The most likely scenario is modest growth with stable margins, resulting in a stock price near current levels.
CHD trades at a trailing PE of 27.6x and forward PE of 25.1x, which is a 25% premium to the industry average of 22x. This premium is justified by its strong margins (net margin 14.7%) and defensive characteristics, but it implies the market expects steady, if not spectacular, growth. The PEG ratio of 1.01 suggests the stock is fairly valued relative to its growth rate, but any slowdown could make it overvalued.
CHD is a reasonable buy for income-focused investors given its 1.4% dividend yield and low beta of 0.47, but the 4% upside to the average analyst target of $105.37 is modest. The stock's premium valuation (PE 27.6x) and flat revenue growth (0.15% YoY) suggest limited near-term upside. It could be a good buy if you believe in margin expansion and long-term brand strength, but for growth investors, better opportunities exist elsewhere.
CHD is better suited for long-term investment due to its defensive nature, low beta (0.47), and consistent dividend payments. Its growth is slow, so short-term traders may find limited volatility and upside. A minimum holding period of 3-5 years is recommended to benefit from compounding dividends and potential margin expansion. The stock's 1-year return of 9.4% is modest, but its stability makes it a core holding for conservative portfolios.